Related Experiment Video
Updated: Apr 27, 2026

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
Published on: February 10, 2023
Expanding the clinical phenotypes of MT-ATP6 mutations
Ester López-Gallardo1, Sonia Emperador1, Abelardo Solano2
1Departamento de Bioquímica, Biología Molecular y Celular, Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain, Centro de Investigaciones Biomédicas en red de Enfermedades Raras (CIBERER), Spain.
Abstract:
Mitochondrial DNA mutations at MT-ATP6 gene are relatively common in individuals suffering from striatal necrosis syndromes. These patients usually do not show apparent histochemical and/or biochemical signs of oxidative phosphorylation dysfunction. Because of this, MT-ATP6 is not typically analyzed in many other mitochondrial disorders that have not been previously associated to mutations in this gene. To correct this bias, we have performed a screening of the MT-ATP6 gene in a large collection of patients suspected of suffering different mitochondrial DNA (mtDNA) disorders. In three cases, biochemical, molecular-genetics and other analyses in patient tissues and cybrids were also carried out. We found three new pathologic mutations. Two of them in patients showing phenotypes that have not been commonly associated to mutations in the MT-ATP6 gene. These results remark the importance of sequencing the MT-ATP6 gene in patients with striatal necrosis syndromes, but also within other mitochondrial pathologies. This gene should be sequenced at least in all those patients suspected of suffering an mtDNA disorder disclosing normal results for histochemical and biochemical analyses of respiratory chain.
Insights
Screening the MT-ATP6 gene identified three new mutations in mitochondrial DNA disorders. This highlights the importance of MT-ATP6 gene sequencing, even in patients without typical oxidative phosphorylation dysfunction signs.
Area of Science:
- Genetics
- Molecular Biology
- Neurology
Background:
- Mitochondrial DNA (mtDNA) mutations in the MT-ATP6 gene are common in striatal necrosis syndromes.
- Patients often lack clear histochemical or biochemical signs of oxidative phosphorylation dysfunction.
- This leads to MT-ATP6 not being routinely screened in many mitochondrial disorders.
Purpose of the Study:
- To investigate the role of MT-ATP6 gene mutations in a broader range of mitochondrial DNA disorders.
- To identify novel pathogenic mutations within the MT-ATP6 gene.
- To correct the diagnostic bias against analyzing MT-ATP6 in atypical cases.
Main Methods:
- Screening of the MT-ATP6 gene in a large cohort of patients with suspected mitochondrial DNA disorders.
- Biochemical, molecular-genetics, and cybrid analyses were performed in selected cases.
- Phenotypic correlation with identified mutations.
Main Results:
- Three novel pathogenic MT-ATP6 gene mutations were identified.
- Two mutations were found in patients with phenotypes not typically associated with MT-ATP6 mutations.
- Confirmed the presence of mutations despite normal oxidative phosphorylation test results in some patients.
Conclusions:
- Sequencing the MT-ATP6 gene is crucial for diagnosing striatal necrosis syndromes.
- MT-ATP6 gene analysis should be extended to other mitochondrial pathologies, especially when respiratory chain analyses are normal.
- This broadens the diagnostic scope for mitochondrial DNA disorders.
More Related Videos
Related Concept Videos
ATP Synthase: Mechanism
ATP Synthase: Structure
Animal Mitochondrial Genetics
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Inborn Errors of Metabolism
Incomplete Dominance

